Literature DB >> 21617097

Heterogeneity of altered cytokine levels across the clinical spectrum of diabetes in China.

Yufei Xiang1, Pengcheng Zhou, Xiaojue Li, Gan Huang, Zhenqi Liu, Aimin Xu, R David Leslie, Zhiguang Zhou.   

Abstract

OBJECTIVE: To determine the relationship between selected cytokines and diabetes in Chinese subjects. RESEARCH DESIGN AND METHODS: Adult patients with recent-onset type 1 diabetes (n=53), latent autoimmune diabetes in adults (LADA) (n=250), and type 2 diabetes (n=285) from multiple centers were compared with normal subjects (n=196). We centrally tested serum GAD antibodies (GADAs), interleukin-6 (IL-6), lipocalin 2 (LCN2), high-sensitivity C-reactive protein (hs-CRP), and adiponectin.
RESULTS: After adjustment for age, sex, and BMI, all diabetes types had increased IL-6 and LCN2 (P<0.01), and all four cytokines were increased in LADA (P<0.01). In type 1 diabetes, adiponectin but not hs-CRP was increased (P<0.01), whereas in type 2 diabetes, hs-CRP but not adiponectin was increased (P<0.01). Adiponectin was correlated positively with GADA titer and negatively with hs-CRP (P<0.01 for both).
CONCLUSIONS: In China, inflammatory markers are increased in all three major types of diabetes, but probably for different reasons, even in autoimmune diabetes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617097      PMCID: PMC3120206          DOI: 10.2337/dc11-0039

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


Altered inflammatory mediators in diabetes could either reflect the cause of the disease or be secondary to metabolic derangements associated with diabetes. In type 2 diabetes, some cytokines (interleukin-6 [IL-6] and lipocalin 2 [LCN2]) are associated with insulin resistance (1) and others, such as serum high-sensitivity C-reactive protein (hs-CRP) and adiponectin, with cardiovascular risk (2,3). If these altered cytokines are secondary to the disease, then we should find them in diabetes, irrespective of type. If they are involved specifically in that disease process, then a specific profile of altered cytokine levels might be found in a particular type of diabetes. We hypothesized that a diabetes type–specific cytokine profile would be associated with autoimmune diabetes and, therefore, found in latent autoimmune diabetes in adults (LADA) and type 1 diabetes.

RESEARCH DESIGN AND METHODS

We studied cross-sectionally clinic- and hospital-based adult diabetic patients (aged >30 years) within 1 year from diagnosis. We ascertained subjects with LADA and type 2 diabetes from the LADA China multicenter study (46 hospitals throughout China contributed); type 1 diabetes, defined by WHO criteria (4), from the Type 1 Diabetes Collaboration Net (18 hospitals in Hunan Province); and normal subjects were screened by 75-g oral glucose tolerance test from 5,000 Chinese in a population-based study. Definition of LADA (5–7) was 1) GAD antibody (GADA) positive, 2) age >30 years at diagnosis, 3) independence from insulin treatment 6 months postdiagnosis, and 4) without ketoacidosis. Type 2 diabetic patients were GADA negative and noninsulin treated 6 months postdiagnosis. Subjects with hs-CRP >10 mg/L or taking anti-inflammatory drugs within 3 months were excluded. Metabolic syndrome was defined by National Cholesterol Education Program-Adult Treatment Panel III criteria (8). This study was approved by ethics committees at Second Xiangya Hospital of Central South University and at each center and conducted according to the Declaration of Helsinki. All participants provided written informed consent. Height, weight, waist circumference, hip circumference, and blood pressure were recorded locally, and fasting sera samples were processed centrally. GADA was measured by radioligand assay (9). ELISA determined high-sensitivity IL-6 (IL-6 HS; R&D Systems, Minneapolis, MN), 7% intraassay and 5% interassay coefficient of variation (CV); LCN2 (10), 3.8–6.0% intraassay and 3.1–5.2% interassay CV; adiponectin (11) 5–6% intraassay and 6–8% interassay CV. Hs-CRP was measured by immunoturbidometric assay (Orine Diagnostica) with 2.1–3.3% intraassay and 3.4–4.6% interassay CV.

Statistical analysis

We used SPSS (version 13; SPSS, Chicago, IL) for statistical analysis. Data are expressed when normally distributed as means ± SD and when skewed as median (25th–75th percentiles). Logarithmic transformations were applied on non–normally distributed parameters before comparison. Frequency differences were compared using χ2 test. Variance analysis compared means by one-way ANOVA as appropriate. We used a general linear model of univariate analysis adjusted for age, sex, and BMI; log-transformed cytokine value was the dependent variable, different diabetes groups were fixed, and age, sex, and BMI were covariates (Fig. 1). Multivariate regression models investigated differences in log-transformed cytokine concentrations (dependent variables), with increasing number of variables (model 1: unadjusted; model 2: sex and age adjusted; model 3: age, sex, and BMI [independent variables] adjusted) (Supplementary Table 2). Linear relationships were evaluated by partial correlations test adjusted age, sex, and BMI. Data were not corrected for multiple comparisons and are descriptive; P < 0.01 was considered significant.
Figure 1

Cytokine levels in subtypes of diabetes and normal subjects. Univariate of general linear model adjusted according to age, sex, and BMI between groups. *P < 0.05, **P < 0.01, ***P < 0.001. NGT, normal glucose tolerance subjects; T1D, type 1 diabetic subjects; T2D, type 2 diabetic subjects.

Cytokine levels in subtypes of diabetes and normal subjects. Univariate of general linear model adjusted according to age, sex, and BMI between groups. *P < 0.05, **P < 0.01, ***P < 0.001. NGT, normal glucose tolerance subjects; T1D, type 1 diabetic subjects; T2D, type 2 diabetic subjects.

RESULTS

Results are shown in Supplementary Table 1. Of 784 subjects, patients with both LADA and type 2 diabetes were significantly older than subjects with normal glucose tolerance or type 1 diabetic patients. As expected, LADA patients had lower insulin secretion than type 2 diabetic patients, while in type 1 diabetic patients, insulin secretion was lower than in both LADA and type 2 diabetic patients. Metabolic syndrome in type 1 diabetic and control subjects was less frequent than in both LADA and type 2 diabetic subjects. We used univariate and multivariate regression models to adjust age, sex, and BMI differences (Fig. 1 and Supplementary Table 2). After adjustment, all three types of diabetes (type 1 diabetes, LADA, and type 2 diabetes) showed increased IL-6 and LCN2. All four cytokines were increased in LADA. In type 1 diabetes, adiponectin but not hs-CRP was increased. In type 2 diabetes, hs-CRP but not adiponectin was increased, and adiponectin was decreased after adjustment. GADA titer was positively correlated with adiponectin (r = 0.14, P < 0.01) and negatively correlated with hs-CRP (r = −0.15, P < 0.001) (Supplementary Tables 3 and 4). In LADA subjects, hs-CRP was strongly related to BMI (r = 0.363, P < 0.001).

CONCLUSIONS

Some inflammatory markers were increased in diabetes (i.e., IL-6 and LCN2) irrespective of diabetes type, implying that cytokine changes are secondary features of the disease independent of obesity, and consistent with a proinflammatory effect in diabetes in general. Nevertheless, obesity (waist-to-hip ratio) was associated with all four cytokines assayed, and the pattern of cytokine changes differed according to diabetes type. Cytokines (IL-6, TNFα, and IL-1 receptor antagonist) in Europeans with these same major diabetes types were also positively associated with BMI, which was higher in diabetic patients than in control subjects and highest in type 2 diabetes but similar in LADA and type 1 diabetes; after correction, only TNFα in LADA and type 1 diabetes was no longer different from that in control subjects (5). In both the European study and this Chinese study, IL-6 showed remarkably similar increases in major diabetes types; IL-6, as well as LCN2, levels were higher than in control subjects and highest in type 2 diabetes (5). However, hs-CRP was increased in both LADA and type 2 diabetes, but not type 1 diabetes, while adiponectin was only increased in LADA and type 1 diabetes. Despite adiponectin being positively correlated with GADA titer, it has no established role in autoimmune diabetes and certainly cannot predict it (12). However, low-grade inflammation could be important in autoimmunity, potentially explaining any benefit of rosiglitazone (13). Indeed, each cytokine (IL-6, LCN2, hs-CRP, and adiponectin) was increased in Chinese LADA, though probably for different reasons (14). Given the relative lack of obesity in China, comparative Chinese and European studies could delineate the relative roles of obesity, diabetes, and autoimmunity on cytokines. Surprisingly, therefore, metabolic syndrome was prevalent in this large LADA cohort, in contrast to European studies (5,6). These results point toward a complex relationship between diabetes types and altered cytokine levels.
  13 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  Interleukin-6 and diabetes: the good, the bad, or the indifferent?

Authors:  Ole P Kristiansen; Thomas Mandrup-Poulsen
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

3.  Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans.

Authors:  Yu Wang; Karen S L Lam; Edward W Kraegen; Gary Sweeney; Jialiang Zhang; Annette W K Tso; Wing-Sun Chow; Nelson M S Wat; Jian Yu Xu; Ruby L C Hoo; Aimin Xu
Journal:  Clin Chem       Date:  2006-10-13       Impact factor: 8.327

4.  Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4.

Authors:  M N Pham; M I Hawa; C Pfleger; M Roden; G Schernthaner; P Pozzilli; R Buzzetti; W A Scherbaum; W Scherbaum; J Seissler; H Kolb; S Hunter; R D G Leslie; N C Schloot
Journal:  Diabetologia       Date:  2011-02-24       Impact factor: 10.122

5.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.

Authors:  J Danesh; P Whincup; M Walker; L Lennon; A Thomson; P Appleby; J R Gallimore; M B Pepys
Journal:  BMJ       Date:  2000-07-22

6.  Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.

Authors:  Aimin Xu; Shinan Yin; Laiching Wong; Kok Weng Chan; Karen S L Lam
Journal:  Endocrinology       Date:  2003-10-30       Impact factor: 4.736

Review 7.  Adiponectin: A novel adipokine linking adipocytes and vascular function.

Authors:  Barry J Goldstein; Rosario Scalia
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

8.  Adiponectin levels do not predict clinical onset of type 1 diabetes in antibody-positive relatives.

Authors:  I Truyen; J De Grijse; C Van Schravendijk; D De Smet; K Decochez; E Vandemeulebroucke; M Giri; B Keymeulen; C Mathieu; L Van Gaal; P De Pauw; I Weets; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2007-08-09       Impact factor: 10.122

Review 9.  Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin.

Authors:  Eduardo Esteve; Wifredo Ricart; José Manuel Fernández-Real
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

10.  Predicting adult-onset autoimmune diabetes: clarity from complexity.

Authors:  R David Leslie
Journal:  Diabetes       Date:  2010-02       Impact factor: 9.461

View more
  22 in total

1.  Fatty acids modulate cytokine and chemokine secretion of stimulated human whole blood cultures in diabetes.

Authors:  M C Simon; S Bilan; B Nowotny; T Dickhaus; V Burkart; N C Schloot
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

Review 2.  Innate immunity in latent autoimmune diabetes in adults.

Authors:  Juan Huang; James Alexander Pearson; F Susan Wong; Li Wen; Zhiguang Zhou
Journal:  Diabetes Metab Res Rev       Date:  2021-06-22       Impact factor: 4.876

Review 3.  Latent autoimmune diabetes of the adult: current knowledge and uncertainty.

Authors:  E Laugesen; J A Østergaard; R D G Leslie
Journal:  Diabet Med       Date:  2015-02-07       Impact factor: 4.359

4.  Declined plasma sfrp5 concentration in patients with type 2 diabetes and latent autoimmune diabetes in adults.

Authors:  Liqing Cheng; Dongmei Zhang; Bing Chen
Journal:  Pak J Med Sci       Date:  2015       Impact factor: 1.088

5.  Adult-onset autoimmune diabetes identified by glutamic acid decarboxylase autoantibodies: a retrospective cohort study.

Authors:  Eri Wada; Takeshi Onoue; Tamaki Kinoshita; Ayaka Hayase; Tomoko Handa; Masaaki Ito; Mariko Furukawa; Takayuki Okuji; Tomoko Kobayashi; Shintaro Iwama; Mariko Sugiyama; Hiroshi Takagi; Daisuke Hagiwara; Hidetaka Suga; Ryoichi Banno; Motomitsu Goto; Hiroshi Arima
Journal:  Diabetologia       Date:  2021-07-15       Impact factor: 10.122

6.  Relationships between Islet-Specific Autoantibody Titers and the Clinical Characteristics of Patients with Diabetes Mellitus.

Authors:  Yiqian Zhang; Tong Yin; Xinlei Wang; Rongping Zhang; Jie Yuan; Yi Sun; Jing Zong; Shiwei Cui; Yunjuan Gu
Journal:  Diabetes Metab J       Date:  2020-07-21       Impact factor: 5.376

7.  Serum retinol-binding protein 4 as a marker for cardiovascular disease in women.

Authors:  Khalid M Alkharfy; Nasser M Al-Daghri; Paul M Vanhoutte; Soundararajan Krishnaswamy; Aimin Xu
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

8.  Variation of C peptide decay rate in diabetic patients with positive glutamic acid decarboxylase antibody: better discrimination with initial fasting C peptide.

Authors:  Xia Li; Gan Huang; Jian Lin; Lin Yang; Zhiguang Zhou
Journal:  BMC Endocr Disord       Date:  2013-03-01       Impact factor: 2.763

9.  Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study.

Authors:  Zhiguang Zhou; Yufei Xiang; Linong Ji; Weiping Jia; Guang Ning; Gan Huang; Lin Yang; Jian Lin; Zhenqi Liu; William A Hagopian; R David Leslie
Journal:  Diabetes       Date:  2012-10-18       Impact factor: 9.461

10.  Proinflammatory and prothrombotic state in subjects with different glucose tolerance status before cardiovascular disease.

Authors:  Irma Isordia-Salas; María Eugenia Galván-Plata; Alfredo Leaños-Miranda; Eberth Aguilar-Sosa; Francisco Anaya-Gómez; Abraham Majluf-Cruz; David Santiago-Germán
Journal:  J Diabetes Res       Date:  2014-03-17       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.